PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 13, 2025Annals of Medicine4 citationsOpen Access

Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study

View Full Paper
YXYan XiaoZXZhong XieKOKaobin Ouyang

Key Points

  • Disitamab vedotin plus PD-1 inhibitor improved treatment outcomes in advanced gastric cancer patients.
  • In a cohort of pre-treated patients, safety and efficacy were assessed, highlighting significant findings.
  • The study utilized a retrospective design across multiple centers to evaluate real-world application.
  • The results support the need for further research into combination therapies for advanced HER2 overexpressed gastric cancer.

Abstract

Background The efficacy of pre-treated advanced gastric or gastroesophageal junction cancer (G/GEJC) with HER2 overexpressed (IHC 2+/3+) remains unsatisfactory. This retrospective real-world study aimed to analyse the safety and efficacy of disitamab vedotin (RC48) plus programmed death-1 (PD-1) inhibitor in pre-treated patients with advanced G/GEJC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xiao et al. (2025) studied this question.

synapsesocial.com/papers/68ec51df42911f61ef8b2243https://doi.org/10.1080/07853890.2025.2569994
Ask AI
Helpful
Bookmark
Share
View Full Paper